Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
226 studies found for:    b47
Show Display Options
Rank Status Study
1 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Docetaxel;   Drug: Cyclophosphamide;   Biological: Trastuzumab;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
2 Recruiting EyeBag Effectiveness in Meibomian Gland Dysfunction
Condition: Meibomian Gland Dysfunction
Interventions: Device: EyeBag;   Other: Placebo
3 Recruiting X-chromosome Inactivation, Epigenetics and the Transcriptome
Conditions: Turner Syndrome;   Klinefelter Syndrome;   Triple X Syndrome;   47 XYY Syndrome;   Aortic Aneurysm
Intervention:
4 Recruiting Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)
Condition: Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)
Intervention: Drug: ND-L02-s0201 Injection
5 Unknown  Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy
Conditions: Chronic Hepatitis B;   Hepatocellular Carcinoma
Intervention: Drug: Entecavir
6 Active, not recruiting Cognitive Changes Associated With Breast Cancer Treatment
Conditions: Breast Cancer;   Cognitive Side Effects of Cancer Treatments;   Stage I, II and III A Breast Cancer
Intervention: Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
7 Completed
Has Results
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
8 Recruiting Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28
Conditions: Meningoccocal Disease,;   Meningococcal Meningitis
Interventions: Biological: rMenB + OMV vaccine (1 dose at study month zero);   Biological: rMenB + OMV vaccine (2 doses 1 month apart)
9 Completed Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1);   Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2);   Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3);   Biological: Routine vaccination;   Biological: Meningococcal group C
10 Completed Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: 1a - rMenB+OMV NZ and routine infant vaccinations;   Biological: 1b - rMenB+OMV NZ and routine infant vaccinations;   Biological: 2a - Routine infant vaccinations and rMenB+OMV NZ;   Biological: 2b - rMenB+OMV NZ and routine infant vaccinations;   Biological: 3a - rMenB+OMV NZ and routine infant vaccinations;   Biological: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations;   Biological: 4a- rMenB+OMV NZ and routine infant vaccinations;   Biological: 4b - rMenB+OMV NZ and routine infant vaccinations
11 Active, not recruiting Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine
Condition: Malaria
Interventions: Biological: Pfs25-EPA;   Biological: Euvax/Hepatitis B vaccine;   Biological: Menatra/Meningococcal Groups A, C, Y, W-135 vaccine;   Biological: Alhydrogel
12 Unknown  The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection
Condition: Hepatitis B Virus
Interventions: Drug: Peginterferon + Vitamin D;   Drug: Peginterferon;   Drug: Sebivo;   Drug: entecavir+ vitamin d
13 Active, not recruiting Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Condition: Chronic Hepatitis B
Interventions: Drug: entecavir;   Drug: Other anti-HBV medication
14 Terminated An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
Condition: Hepatitis B, Chronic
Intervention:
15 Completed A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin;   Drug: Placebo for ribavirin
16 Completed
Has Results
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease
Condition: Hepatitis C, Chronic
Interventions: Drug: eltrombopag;   Drug: placebo
17 Recruiting Prognostic Potential Cell Surface Marker and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors
Conditions: Solid Tumor;   Ovarian Cancer;   Non-small Cell Lung Cancer;   Chronic Lymphocytic Leukemia;   Burkitt's Lymphoma
Intervention:
18 Completed Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients
Condition: Hepatitis C
Interventions: Drug: BMS-790052 (Daclatasvir);   Drug: Telaprevir;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
19 Recruiting B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Rituximab
20 Not yet recruiting B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.
Condition: Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME)
Interventions: Drug: Rituximab;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years